TNF CMO Mitchell Glass, M.D., presented an abstract at the @Gerisoc Spring Meeting 2025 on the small-molecule TNF-alpha inhibitor, #isomyosamine, which has shown potential for regulating pro-inflammatory cytokines associated with #sarcopenia. bit.ly/4jCxX68 $TFNA

TNF CMO Mitchell Glass, M.D. comments, “We are currently enrolling patients in a larger Phase 2b #clinicaltrial that will investigate isomyosamine’s effect on cellular inflammation and recovery of ambulation speed." Read more: bit.ly/4jCxX68 $TNFA #Biopharma

Positive clinical data validates commencement of a larger Phase 2b #clinicaltrial in elderly patients post-hip fracture. bit.ly/4jCxX68 $TNFA

TNF’s drug, isomyosamine, shown to decrease biomarkers associated with TNF-alpha activation in elderly patients with sarcopenia. bit.ly/4jCxX68 $TNFA

TNF Pharmaceuticals and Renova Health Utilize #AI to Accelerate Drug Development. Read the press release: bit.ly/42BbwqR $TNFA #Biopharma #MachineLearning #GLP1

ICYMI: TNF and Renova Health are leveraging #AI and #machinelearning to identify high-risk patient groups for studies of muscle mass preservation during GLP-1 treatment. bit.ly/42BbwqR $TNFA #Biopharma #GLP1 #DrugDevelopment

TNF Pharma, Renova collaborate on AI-powered drug development. Read how #machinelearning technology is used to identify patients for studies of muscle mass preservation during GLP-1 treatment via World Pharmaceuticals Frontier: bit.ly/42WqGIB $TNFA #AI #ML #Biopharma

TNF CMO Mitchell Glass, M.D., comments, “Renova Health has used its #AI and #ML technology platform to analyze and identify optimal patient pools and study sites, enabling a swift progression of our study series over the coming months." bit.ly/42BbwqR $TNFA #Biopharma

TNF and Renova Health use #AI to identify patients for #GLP1 treatments. The partnership is analyzing data from 30,000 patients to identify high-risk patients. Dive in via @Pharmatechfocus: bit.ly/4jQYIE1 $TNFA #Biopharma #ML #Diabetes #Weightloss

TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists. Read the press release here: bit.ly/4dbw7an $TNFA #GLP1 #Biopharma #AI #Sarcopenia #ClinicalResearch

TNF and Renova Health’s first study examines pro-inflammatory TNF-α in #patients on #GLP1 agonists, incl. #Wegovy or #Ozempic. Findings show isomyosamine’s potential to impact quality of life in general practice populations. ICYMI: bit.ly/4dbw7an $TNFA #Biopharma #AI

TNF CMO Mitchell Glass, M.D., comments: “Our goal for our #GLP1 study series is to identify patients who are taking GLP-1 agonists to test whether isomyosamine can decrease inflammation and prevent or ameliorate the risk of adverse outcomes.” bit.ly/4dbw7an $TNFA

TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease. Read the press release: bit.ly/4eo3jMs $TNFA #RareDisease #Immunology #ClinicalResearch

TNF formed a philanthropic collaboration with the DADA2 Foundation to initiate a Compassionate Use study evaluating isomyosamine as a potential treatment for #DADA2. Read more: bit.ly/4eo3jMs $TNFA #TNFInhibitor #Immunology #RareDisease

"The body of evidence surrounding DADA2 has shown that TNF inhibition is the most effective treatment for the hyperinflammatory and vasculitic aspects of this disease," said Mitchell Glass, M.D., TNF CMO. bit.ly/4eo3jMs $TNFA #TNFInhibition #RareDisease #Vasculitis

TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation. Read the press release here: bit.ly/3Hkuvj7 $TNFA #BusinessUpdate

TNF Pharmaceuticals Secures Exclusive Global Rights to Innovative Light Speed Computing Accelerator for Use in Cryptocurrency Applications. Read the press release here: bit.ly/47V6x8D $TNFA #Crypto #HPC #PhotonicComputing

TNF Pharmaceuticals Announces Closing of $7 Million Private Placement. Read the press release here: bit.ly/4p1H5o9 $TNFA #BusinessUpdate

TNF Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference. Read the press release here: bit.ly/3VCXCkZ $TNFA H.C. Wainwright & Co. #HCWConference

TNF Pharmaceuticals is pleased to have regained compliance with Nasdaq’s listing standards. This milestone comes as we work to build a strong strategic platform for growth and shareholder value. Read the press release: bit.ly/4gra1Cl $TNFA